Ad is loading...
GSK
Price
$33.70
Change
+$0.35 (+1.05%)
Updated
Nov 21 closing price
75 days until earnings call
SNY
Price
$47.98
Change
+$0.20 (+0.42%)
Updated
Nov 21 closing price
69 days until earnings call
Ad is loading...

GSK vs SNY

Header iconGSK vs SNY Comparison
Open Charts GSK vs SNYBanner chart's image
GSK
Price$33.70
Change+$0.35 (+1.05%)
Volume$7.03M
CapitalizationN/A
Sanofi ADS
Price$47.98
Change+$0.20 (+0.42%)
Volume$1.83M
CapitalizationN/A
GSK vs SNY Comparison Chart
Loading...
GSK
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SNY
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
GSK vs. SNY commentary
Nov 22, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GSK is a StrongSell and SNY is a Sell.

COMPARISON
Comparison
Nov 22, 2024
Stock price -- (GSK: $33.70 vs. SNY: $47.98)
Brand notoriety: GSK and SNY are both not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: GSK: 112% vs. SNY: 70%
Market capitalization -- GSK: $88.13B vs. SNY: $122.61B
GSK [@Pharmaceuticals: Major] is valued at $88.13B. SNY’s [@Pharmaceuticals: Major] market capitalization is $122.61B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GSK’s FA Score shows that 2 FA rating(s) are green whileSNY’s FA Score has 2 green FA rating(s).

  • GSK’s FA Score: 2 green, 3 red.
  • SNY’s FA Score: 2 green, 3 red.
According to our system of comparison, GSK is a better buy in the long-term than SNY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GSK’s TA Score shows that 4 TA indicator(s) are bullish while SNY’s TA Score has 4 bullish TA indicator(s).

  • GSK’s TA Score: 4 bullish, 5 bearish.
  • SNY’s TA Score: 4 bullish, 2 bearish.
According to our system of comparison, SNY is a better buy in the short-term than GSK.

Price Growth

GSK (@Pharmaceuticals: Major) experienced а -0.89% price change this week, while SNY (@Pharmaceuticals: Major) price change was +0.33% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -2.99%. For the same industry, the average monthly price growth was -8.46%, and the average quarterly price growth was +0.45%.

Reported Earning Dates

GSK is expected to report earnings on Feb 05, 2025.

SNY is expected to report earnings on Jan 30, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-2.99% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SNY($123B) has a higher market cap than GSK($88.1B). SNY has higher P/E ratio than GSK: SNY (20.80) vs GSK (14.01). SNY YTD gains are higher at: 0.571 vs. GSK (-5.475). SNY has higher annual earnings (EBITDA): 12.6B vs. GSK (9.08B). SNY has more cash in the bank: 8.98B vs. GSK (4.99B). GSK (18B) and SNY (18.4B) have identical debt. SNY has higher revenues than GSK: SNY (46.4B) vs GSK (30.3B).
GSKSNYGSK / SNY
Capitalization88.1B123B72%
EBITDA9.08B12.6B72%
Gain YTD-5.4750.571-959%
P/E Ratio14.0120.8067%
Revenue30.3B46.4B65%
Total Cash4.99B8.98B56%
Total Debt18B18.4B98%
FUNDAMENTALS RATINGS
GSK vs SNY: Fundamental Ratings
GSK
SNY
OUTLOOK RATING
1..100
5857
VALUATION
overvalued / fair valued / undervalued
1..100
5
Undervalued
6
Undervalued
PROFIT vs RISK RATING
1..100
10056
SMR RATING
1..100
5080
PRICE GROWTH RATING
1..100
8061
P/E GROWTH RATING
1..100
811
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GSK's Valuation (5) in the Pharmaceuticals Major industry is in the same range as SNY (6). This means that GSK’s stock grew similarly to SNY’s over the last 12 months.

SNY's Profit vs Risk Rating (56) in the Pharmaceuticals Major industry is somewhat better than the same rating for GSK (100). This means that SNY’s stock grew somewhat faster than GSK’s over the last 12 months.

GSK's SMR Rating (50) in the Pharmaceuticals Major industry is in the same range as SNY (80). This means that GSK’s stock grew similarly to SNY’s over the last 12 months.

SNY's Price Growth Rating (61) in the Pharmaceuticals Major industry is in the same range as GSK (80). This means that SNY’s stock grew similarly to GSK’s over the last 12 months.

GSK's P/E Growth Rating (8) in the Pharmaceuticals Major industry is in the same range as SNY (11). This means that GSK’s stock grew similarly to SNY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GSKSNY
RSI
ODDS (%)
Bullish Trend 1 day ago
66%
Bullish Trend 1 day ago
65%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
43%
Bullish Trend 1 day ago
48%
Momentum
ODDS (%)
Bearish Trend 3 days ago
53%
N/A
MACD
ODDS (%)
Bearish Trend 1 day ago
55%
N/A
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
51%
Bullish Trend 1 day ago
54%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
51%
Bearish Trend 1 day ago
40%
Advances
ODDS (%)
Bullish Trend 17 days ago
53%
Bullish Trend 4 days ago
54%
Declines
ODDS (%)
Bearish Trend 2 days ago
54%
Bearish Trend 2 days ago
47%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
56%
Bullish Trend 1 day ago
64%
Aroon
ODDS (%)
Bearish Trend 1 day ago
55%
Bearish Trend 1 day ago
44%
View a ticker or compare two or three
Ad is loading...
GSK
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SNY
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CAR101.642.58
+2.60%
Avis Budget Group
KALA6.550.12
+1.87%
Kala BIO
GOOS9.500.17
+1.82%
Canada Goose Holdings
NUE149.991.82
+1.23%
Nucor Corp
GROY1.310.01
+0.77%
Gold Royalty Corp

GSK and

Correlation & Price change

A.I.dvisor indicates that over the last year, GSK has been loosely correlated with NVS. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if GSK jumps, then NVS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GSK
1D Price
Change %
GSK100%
+1.05%
NVS - GSK
40%
Loosely correlated
+0.74%
GLAXF - GSK
36%
Loosely correlated
-0.53%
JNJ - GSK
34%
Loosely correlated
+1.56%
AZN - GSK
34%
Loosely correlated
+1.68%
SNY - GSK
33%
Poorly correlated
+0.42%
More